# GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma

> **NCT05242146** · PHASE1 · TERMINATED · sponsor: **GB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.** · enrollment: 12 (actual)

## Conditions studied

- CNS Lymphoma

## Interventions

- **DRUG:** GB5121

## Key facts

- **NCT ID:** NCT05242146
- **Lead sponsor:** GB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-05-24
- **Primary completion:** 2023-05-11
- **Final completion:** 2023-05-11
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2023-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05242146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05242146, "GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05242146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*